Real-time enrollment status for this relapsed or refractory multiple myeloma clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 5:24 PM UTC
| NCT Number | NCT06375044 |
| Recruiting Status | Recruiting |
| Condition | Relapsed or Refractory Multiple Myeloma |
| Phase | PHASE1 |
| Target Enrollment | 130 participants |
| Active Locations | 9 sites in the US |
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Last Updated on CT.gov | August 28, 2026 (Aug 28, 2026) |
As of October 12, 2026: Clinical trial NCT06375044 is currently recruiting participants. This phase1 study for relapsed or refractory multiple myeloma is actively seeking new participants at 9 locations across the United States. The study is sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06375044 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 9 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06375044 was last updated Aug 28, 2026 (August 28, 2026). HelloStudys verifies this status automatically.